These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31841758)

  • 1. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target.
    Hashemi V; Maleki LA; Esmaily M; Masjedi A; Ghalamfarsa G; Namdar A; Yousefi M; Yousefi B; Jadidi-Niaragh F
    Int Immunopharmacol; 2020 Jan; 78():106087. PubMed ID: 31841758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
    Stenström J; Hedenfalk I; Hagerling C
    Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
    Yoshida K; Okamoto M; Sasaki J; Kuroda C; Ishida H; Ueda K; Ideta H; Kamanaka T; Sobajima A; Takizawa T; Tanaka M; Aoki K; Uemura T; Kato H; Haniu H; Saito N
    BMC Cancer; 2020 Jan; 20(1):25. PubMed ID: 31914969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells.
    Cai B; Ma P; Ding P; Sun DW; Bu Q; Zhang J
    APMIS; 2020 Mar; 128(3):260-269. PubMed ID: 31811667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
    Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
    Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.
    Bhattacharya S; Muhammad N; Steele R; Peng G; Ray RB
    Oncotarget; 2016 May; 7(22):33202-9. PubMed ID: 27120805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
    Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
    Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model.
    Wang R; Feng W; Wang H; Wang L; Yang X; Yang F; Zhang Y; Liu X; Zhang D; Ren Q; Feng X; Zheng G
    Cancer Lett; 2020 Jan; 469():151-161. PubMed ID: 31669202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.
    Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H
    Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
    Toor SM; Syed Khaja AS; Alkurd I; Elkord E
    Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle.
    Hatzioannou A; Boumpas A; Papadopoulou M; Papafragkos I; Varveri A; Alissafi T; Verginis P
    Front Immunol; 2021; 12():731947. PubMed ID: 34539668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
    Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
    Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCL1 is a major regulatory T cell attracting factor in human breast cancer.
    Kuehnemuth B; Piseddu I; Wiedemann GM; Lauseker M; Kuhn C; Hofmann S; Schmoeckel E; Endres S; Mayr D; Jeschke U; Anz D
    BMC Cancer; 2018 Dec; 18(1):1278. PubMed ID: 30572845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity.
    Luo CT; Liao W; Dadi S; Toure A; Li MO
    Nature; 2016 Jan; 529(7587):532-6. PubMed ID: 26789248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.
    Hossain DM; Panda AK; Chakrabarty S; Bhattacharjee P; Kajal K; Mohanty S; Sarkar I; Sarkar DK; Kar SK; Sa G
    Immunology; 2015 Apr; 144(4):561-73. PubMed ID: 25284464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.
    Saito T; Nishikawa H; Wada H; Nagano Y; Sugiyama D; Atarashi K; Maeda Y; Hamaguchi M; Ohkura N; Sato E; Nagase H; Nishimura J; Yamamoto H; Takiguchi S; Tanoue T; Suda W; Morita H; Hattori M; Honda K; Mori M; Doki Y; Sakaguchi S
    Nat Med; 2016 Jun; 22(6):679-84. PubMed ID: 27111280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
    Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.